
Erasca Faces Class Action Lawsuit After Patent Claims and Patient Death
A 48 percent collapse in Erasca, Inc. share price has triggered a securities class action lawsuit, following revelations that the precision oncology firm faces patent infringement allegations from Revolution Medicines and disclosed the death of a patient enrolled in an ERAS-0015 clinical trial.
























